Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06980623 · ClinicalTrials.gov registry record

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

A clinical trial of Heart Failure and Type 2 Diabetes, sponsored by Brigham and Women's Hospital.

Active
Registry status
26,000
Enrollment target
1
Study location

NCT06980623: Active study of Heart Failure and Type 2 Diabetes, sponsored by Brigham and Women's Hospital.

NCT06980623 is a study of Heart Failure and Type 2 Diabetes that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 26,000 participants, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1210% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06980623, a study of Heart Failure and Type 2 Diabetes, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
26,000 participants
Enrollment target
1
Study location

Study Summary

This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.

Primary Outcome

Cardiovascular outcome includes hospitalization for HF and all-cause mortality

Conditions Studied

Heart Failure Type 2 Diabetes

Interventions

  • DRUG Tirzepatide
  • DRUG Semaglutide

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 26,000 participants
Start Date 2025-01-01
Est. Completion 2026-03-01
Brigham and Women's Hospital

937 total trials

What the registry record for NCT06980623 still lists

NCT06980623 is an observational study that tracks outcomes without assigning an intervention. Its 26,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1210% higher).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.

NCT06980623 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06980623 about?

NCT06980623 is a clinical study titled "Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction". This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.

What is the current status of trial NCT06980623?

This trial is currently active not recruiting. The enrollment target is 26,000 participants. The study started on 2025-01-01. Estimated completion is 2026-03-01.

What conditions does trial NCT06980623 study?

This clinical trial studies the following conditions: Heart Failure, Type 2 Diabetes.

What interventions are being tested in trial NCT06980623?

The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG).

Who is sponsoring clinical trial NCT06980623?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06980623 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06980623's enrollment target sits among peer trials

26,000 6th of 397 higher than 392 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07300839 · 25,500 participants · Phase 3

    A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

  • NCT03175302 · 25,240 participants

    PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing

  • NCT04678193 · 27,000 participants

    COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

  • NCT04595201 · 25,000 participants

    Clinical Follow-up of Pregnant Subjects Undergoing NIPT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06980623, the US trial registry maintained by the National Library of Medicine. NCT06980623 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.